StockData
Kymera Therapeutics, Inc. logo

Kymera Therapeutics, Inc. (KYMR) stock

KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/30227% above fair value
$121.13−0.39 (-0.32%)

Close on Nov 18, 2026Market cap $10.34BP/E –Yield –

Kymera Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Kymera Therapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$287.57M. For fiscal 2025 it was -$232.89M. The highest annual figure on record is $88.13M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$232.89M–
FY2024Dec 31, 2024-$194.50M–
FY2023Dec 31, 2023-$102.83M–
FY2022Dec 31, 2022-$153.09M–
FY2021Dec 31, 2021-$128.95M-246.3%
FY2020Dec 31, 2020$88.13M+392.2%
FY2019Dec 31, 2019$17.91M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$77.91M–
Q2 FY2026Jun 30, 2026-$54.07M–
Q1 FY2026Mar 31, 2026-$88.84M–
Q4 FY2025Dec 31, 2025-$66.75M–
Q3 FY2025Sep 30, 2025-$27.11M–
Q2 FY2025Jun 30, 2025-$59.88M–
Q1 FY2025Mar 31, 2025-$79.15M–
Q4 FY2024Dec 31, 2024-$61.78M-868.0%
Q3 FY2024Sep 30, 2024-$50.19M–
Q2 FY2024Jun 30, 2024-$42.94M–
Q1 FY2024Mar 31, 2024-$39.59M–
Q4 FY2023Dec 31, 2023$8.05M–
Q3 FY2023Sep 30, 2023-$31.65M–
Q2 FY2023Jun 30, 2023-$35.26M–
Q1 FY2023Mar 31, 2023-$43.97M–
Q4 FY2022Dec 31, 2022-$39.54M–
Q3 FY2022Sep 30, 2022-$34.27M–
Q2 FY2022Jun 30, 2022-$38.99M–
Q1 FY2022Mar 31, 2022-$40.30M–
Q4 FY2021Dec 31, 2021-$38.35M–
Q3 FY2021Sep 30, 2021-$37.26M-128.3%
Q2 FY2021Jun 30, 2021-$30.51M–
Q1 FY2021Mar 31, 2021-$22.82M–
Q4 FY2020Dec 31, 2020-$20.07M–
Q3 FY2020Sep 30, 2020$131.67M–
Q2 FY2020Jun 30, 2020-$11.41M–
Q1 FY2020Mar 31, 2020-$12.06M–
Q4 FY2019Dec 31, 2019-$10.80M–

More Kymera Therapeutics figures

See a number that looks wrong?